Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12799292 | 1.00 | LMNA (0.46) | LMNASMN1; SMN2RECQLHTTL3MBTL1 | |
| SCHEMBL13609856 | 1.00 | LMNA (0.46) | LMNASMN1; SMN2RECQLHTTL3MBTL1 | |
| SCHEMBL15362285 | 0.88 | LMNA (0.48) | LMNASMN1; SMN2RECQLHTTL3MBTL1 | |
| SCHEMBL12799291 | 0.78 | HTT (0.35) | LMNASMN1; SMN2RECQLHTTL3MBTL1 | |
| SCHEMBL15362297 | 0.75 | LMNA (0.40) | LMNASMN1; SMN2RECQLHTTL3MBTL1 | |
| SCHEMBL15362301 | 0.75 | LMNA (0.40) | LMNASMN1; SMN2RECQLHTTL3MBTL1 | |
| SCHEMBL17831028 | 0.74 | HTT (0.34) | LMNASMN1; SMN2RECQLHTTL3MBTL1 | |
| SCHEMBL19866709 | 0.70 | LMNA (0.55) | LMNASMN1; SMN2RECQLHTTL3MBTL1 | |
| SCHEMBL14115872 | 0.70 | LMNA (0.55) | LMNASMN1; SMN2RECQLHTTL3MBTL1 | |
| SCHEMBL24708055 | 0.70 | MTNR1A (0.38) | SMN1; SMN2HTTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160166717-A1 | RADIOLABELLING METHOD | GE HEALTHCARE LIMITED (GB) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166717-A1 | RADIOLABELLING METHOD | QPCT, ARF5, PAICS | LMNA 4174/4885SMN1; SMN2 4475/4885RECQL 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.